Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2201 - 2225 of 15556 in total

Propyliodone

Radiopaque medium usually in oil; used in bronchography.
Approved

Ramucirumab

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … , and migration of human endothelial cells. ... By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby ... VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Buserelin

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Approved
Investigational
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

1,2-Distearoyllecithin

Approved
Experimental

Artemotil

Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.
Approved
Matched Description: … Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting ... schizonticide specifically indicated for the treatment of chloroquine-resistant _Plasmodium falciparum_ malaria and …
Matched Categories: … Artemisinin and derivatives ... Antiparasitic Products, Insecticides and Repellents …

Tebentafusp

Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T ... ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic ... being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ferrous bisglycinate

Ferrous bisglycinate is a chelate that is used as a source of dietary iron. Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional . It is found in foods for food enrichment or in supplements for the treatment of iron...
Approved
Matched Description: … Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Toripalimab

The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1) - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the...
Approved
Investigational
Matched Description: … production, and thus its overexpression can inhibit T-cell-mediated immune surveillance of tumors. ... through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and ... PD-L2) to its target receptor (PD-1) results in the inhibition of T-cell proliferation and cytokine …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Onasemnogene abeparvovec

Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is...
Approved
Matched Description: … to debilitating and often fatal muscle weakness. ... for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and ... complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …

Empagliflozin

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Iupac: … (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane- …
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart ... [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and empagliflozin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin …

Avacopan

Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in the serum.[A240249, A240254, A227003] The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis...
Approved
Investigational
Matched Iupac: … (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl …
Matched Description: … AAV may be associated with necrotizing and crescentic glomerulonephritis (NCGN). ... , in particular, the interaction between the anaphylatoxin fragment C5a and its cognate C5aR receptor ... [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Alteplase

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase...
Approved
Investigational
Matched Description: … alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and ... thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and ... alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing ... [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra. ... IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eflapegrastim

Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia. It typically develops during the first cycle of chemotherapy...
Approved
Investigational
Matched Description: … risk of morbidity and mortality. ... Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia ... [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Approved
Matched Description: … It is 140 residues long, and is produced using E. coli. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Catridecacog

Coagulation Factor XIII A-Subunit (Recombinant), also known as catridecacog, is a recombinant form of the Factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential...
Approved
Matched Description: … and maintenance of hemostasis [A18581]. ... , including hydrophobic interaction and ion exchange chromatography [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Blood and Blood Forming Organs …

Isopropamide

Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Approved
Vet approved
Matched Iupac: … (3-carbamoyl-3,3-diphenylpropyl)(methyl)bis(propan-2-yl)azanium …
Matched Description: … and hypermotility. ... It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity …
Matched Categories: … Alimentary Tract and Metabolism ... isopropamide and psycholeptics …

Bimekizumab

Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.[L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor,...
Approved
Investigational
Matched Description: … [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. ... compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and ... of moderate-to-severe psoriasis,[A244450,A244455] likely owing to its dual inhibition of both IL-17A and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Alpha-1-proteinase inhibitor

Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Approved
Matched Description: … inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Guanethidine

An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]
Approved
Matched Description: … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes …
Matched Categories: … guanethidine and diuretics ... Antiglaucoma Preparations and Miotics ... Guanidine Derivatives and Diuretics …

Isatuximab

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the...
Approved
Investigational
Matched Description: … L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and ... dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Cefpirome

Approved
Matched Iupac: … 1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl …

Oxyphencyclimine

Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
Approved
Matched Iupac: … (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate …
Matched Categories: … Alimentary Tract and Metabolism ... oxyphencyclimine and psycholeptics …

Zanubrutinib

Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK...
Approved
Investigational
Matched Description: … [L39030] This indication is valid in the US, Europe, and Canada. ... aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and ... A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Cyclosporine

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products...
Approved
Investigational
Vet approved
Matched Description: … treat various inflammatory and autoimmune conditions. ... calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and ... [A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 2201 - 2225 of 15556 in total